Moderna, Inc. (MRNA)
195.00
-4.33
(-2.17%)
USD |
NASDAQ |
Nov 20, 16:00
199.06
+4.06
(+2.08%)
After-Hours: 20:00
Moderna Research and Development Expense (TTM) : 2.401B for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 2.401B |
| June 30, 2026 | 2.635B |
| March 31, 2026 | 2.69B |
| December 31, 2025 | 2.917B |
| September 30, 2025 | 3.271B |
| June 30, 2025 | 3.607B |
| March 31, 2025 | 4.144B |
| December 31, 2024 | 4.354B |
| September 30, 2024 | 4.496B |
| June 30, 2024 | 4.322B |
| March 31, 2024 | 4.20B |
| December 31, 2023 | 4.226B |
| September 30, 2023 | 4.153B |
| June 30, 2023 | 3.949B |
| March 31, 2023 | 3.525B |
| December 31, 2022 | 2.947B |
| September 30, 2022 | 2.386B |
| Date | Value |
|---|---|
| June 30, 2022 | 2.13B |
| March 31, 2022 | 1.848B |
| December 31, 2021 | 1.759B |
| September 30, 2021 | 1.940B |
| June 30, 2021 | 1.825B |
| March 31, 2021 | 1.617B |
| December 31, 2020 | 1.339B |
| September 30, 2020 | 697.74M |
| June 30, 2020 | 474.10M |
| March 31, 2020 | 450.64M |
| December 31, 2019 | 466.05M |
| September 30, 2019 | 506.67M |
| June 30, 2019 | 503.38M |
| March 31, 2019 | 487.06M |
| December 31, 2018 | 454.08M |
| September 30, 2018 | 421.48M |
| June 30, 2018 | 406.04M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Revolution Medicines, Inc. | 1.439B |
| Vaxcyte, Inc. | 1.093B |
| BioNTech SE | 2.378B |
| Vir Biotechnology, Inc. | 402.51M |
| GRAIL, Inc. | 183.98M |